MS 247

Drug Profile

MS 247

Latest Information Update: 31 Aug 2007

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Nihon Schering
  • Class Antineoplastics
  • Mechanism of Action Alkylating agents; Apoptosis stimulants; DNA cross linking agents; DNA inhibitors; DNA topoisomerase inhibitors; Mitosis inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Cancer

Most Recent Events

  • 10 Oct 2000 A preclinical study has been added to the pharmacodynamics section
  • 27 Mar 2000 Mitsui Pharmaceuticals has been acquired by Schering AG
  • 26 Oct 1999 A preclinical study has been added to the pharmacodynamics and adverse events sections
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top